<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Immunocompetent AML Model for Preclinical Efficacy Testing

Acute myeloid leukemia (AML) treatment options stagnated for many years, until the approval of multiple targeted agents in 2017. The advance of immunotherapeutics, and the approval of immune checkpoint inhibitors, is also offering new treatment options in hematological malignancies.